Literature DB >> 3530307

Prostacyclin and thromboxane in benign and malignant breast tumours.

G M Laekeman, I B Vergote, G M Keersmaekers, J Heiremans, C F Haensch, G de Roy, F L Uyttenbroeck, A G Herman.   

Abstract

6-keto-PGF1 alpha and thromboxane B2 were determined by radioimmunoassay in 37 extracts of breast carcinomata, 8 fibroadenomata, 12 sclerocystic-disease specimens and 51 normal breast tissues. More prostanoids were extracted from carcinomata than from normal specimens, fibroadenomata or sclerocystic-disease tissues (P less than 0.05). The 6-keto-PGF1 alpha/TXB2 ratio was higher in carcinomata than in normal tissues and fibroadenomata (P less than 0.05) but was not significantly different from the ratio in sclerocystic disease. The prostaglandin levels and the 6-keto-PGF1 alpha/TXB2 ratios from carcinomata did not correlate significantly with age, tumour size, differentiation, lymph node status, nuclear-cytoplasmic ratio, host cell reaction, mast cells, necrosis, elastosis, fibrosis or blood vessel density. Lower nuclear density was associated with lower 6-keto-PGF1 alpha/TXB2 ratios (P = 0.01) whereas the latter value was higher when infiltration was lower (P = 0.03). There was a positive correlation between mitotic index and the 6-keto-PGF1 alpha/TXB2 ratio (P = 0.04). Cumulation of variables revealed lower prostanoid ratios in tumours greater than 2 cm without lymph node metastasis then tumours less than 2 cm with lymph node metastasis (P = 0.04). A first follow-up (14 months) showed a higher 6-keto-PGF1 alpha/TXB2 ratio in patients who developed metastasis (P = 0.04). Our study does not confirm the hypothesis that high prostacyclin levels are a good prognostic index in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3530307      PMCID: PMC2001625          DOI: 10.1038/bjc.1986.194

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Increasing the efficiency of cancer chemotherapy with heparin: "clinical study".

Authors:  E G Elias; F Sepulveda; I B Mink
Journal:  J Surg Oncol       Date:  1973       Impact factor: 3.454

2.  Macrophages synthesis and release prostaglandins in response to inflammatory stimuli.

Authors:  J L Humes; R J Bonney; L Pelus; M E Dahlgren; S J Sadowski; F A Kuehl; P Davies
Journal:  Nature       Date:  1977-09-08       Impact factor: 49.962

3.  Pharmacological control of prostaglandin and thromboxane release from macrophages.

Authors:  K Brune; M Glatt; H Kälin; B A Peskar
Journal:  Nature       Date:  1978-07-20       Impact factor: 49.962

4.  Radioimmunoassay of prostaglandins and thromboxanes.

Authors:  E Granström; H Kindahl
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1978

5.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.

Authors:  S Moncada; R Gryglewski; S Bunting; J R Vane
Journal:  Nature       Date:  1976-10-21       Impact factor: 49.962

6.  Prostaglandins as mediators of bone resorption in renal and breast tumours.

Authors:  M Greaves; K J Ibbotson; D Atkins; T J Martin
Journal:  Clin Sci (Lond)       Date:  1980-03       Impact factor: 6.124

7.  Breast cancer, prostaglandins, and bone metastases.

Authors:  A Bennett; A M McDonald; J S Simpson; I F Stamford
Journal:  Lancet       Date:  1975-05-31       Impact factor: 79.321

8.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

Authors:  M Hamberg; J Svensson; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

9.  The inhibitory effect of heparin and warfarin treatments on the intravascular survival of B16 melanoma cells in syngeneic C57 mice.

Authors:  A Lione; H B Bosmann
Journal:  Cell Biol Int Rep       Date:  1978-01

10.  Prostaglandin F2 alpha in benign and malignant breast tumours.

Authors:  I B Vergote; G M Laekeman; G H Keersmaekers; F L Uyttenbroeck; J S Vanderheyden; G P Albertyn; C F Haensch; G J De Roy; A G Herman
Journal:  Br J Cancer       Date:  1985-06       Impact factor: 7.640

View more
  4 in total

Review 1.  Clinical significance of prostacyclin and thromboxane in cancer of the female breast and genital tract.

Authors:  S Nigam; A Zakrzewicz; S Eskafi; A Roscher
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

2.  Characterization of immortalized mouse granulosa cell lines.

Authors:  T W Briers; A van de Voorde; H Vanderstichele
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-11       Impact factor: 2.416

3.  Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.

Authors:  B A Teicher; T T Korbut; K Menon; S A Holden; G Ara
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Expression of Prostacyclin-Synthase in Human Breast Cancer: Negative Prognostic Factor and Protection against Cell Death In Vitro.

Authors:  Thomas Klein; Jens Benders; Friederike Roth; Monika Baudler; Isabel Siegle; Martin Kömhoff
Journal:  Mediators Inflamm       Date:  2015-07-27       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.